参考文献
[1] Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions[J]. Circ Res. 2013;113（6）:810–834.
[2] Assmus B, Rolf A, Erbs S, et al; REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction[J]. Circ Heart Fail. 2010;3（1）:89–96.
[3] Schaefer A, Zwadlo C, Fuchs M, Meyer GP, Lippolt P, Wollert KC, Drexler H. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial–an echocardiographic study[J]. Eur J Echocardiogr. 2010;11（2）:165–171.
[4] Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial[J]. Lancet. 2011;378（9806）:1847–1857.
[5] Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, Pappas P, Tatooles A, Stoddard MF, Lima JA, Slaughter MS, Anversa P, Bolli R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance[J]. Circulation. 2012;126（11 Suppl 1）:S54–S64.
[6] Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart[J]. J Mol Cell Cardiol. 2011;50（2）:280–289.
[7] Hong KU, Guo Y, Li QH, Cao P, Al-Maqtari T, Vajravelu BN, Du J, Book MJ, Zhu X, Nong Y, Bhatnagar A, Bolli R. c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart[J]. PLoS One. 2014;9:e96725.
[8] Ye, Z., Zhou, Y., Cai, H., and Tan, W. Myocardial regeneration: Roles of stem cells and hydrogels. Adv. Drug Deliv[J]. Rev. 2011; 63（8）:688–697.
[9] Karam JP, Muscari C, Montero-Menei CN. Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium[J]. Biomaterials. 2012;33(23):5683–5695.
[10] Ren S, Jiang X, Li Z, Wen Y, Chen D, Li X, Zhang X, Zhuo R, Chu H. Physical properties of poly(N-isopropylacrylamide) hydrogel promote its effects on cardiac protection after myocardial infarction[J]. J Int Med Res. 2012;40(6):2167–2182.
[11] Yang Z, von Ballmoos MW, Faessler D, et al. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells[J]. Atherosclerosis, 2010, 211(1):103-9.
[12]Barile, L, Messina, E, Giacomello, A, Et al.Endogenous cardiac stem cells[J]. Prog Cardiovasc Dis, 2007,50(1):31-48.
[13] van Vliet P, Sluijter J.P, Doevendans PA, et al. Isolation and expansion of resident cardiac progenitor cells[J]. Expert. Rev. Cardiovasc. Ther,2007,5(1):33-43.
[14]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology[J]. Nat Protoc,2009,4(2):232e43.
[15]Chugh AR, Beache GM, Loughran JH,et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance[J]. Circulation.2012,126(11 Suppl 1):S54-64.
[16]Koichi IMAI, Kazuhiko SUESE, Tsukasa AKASAKA, et al. In Vitro Study of Cell Differentiation by Mouse Embryo Stem Cells on Nanocarbon Tubes[J]. Nano Biomedicine, 2010, 2(1) 47-51.
[17] Chen K, Wu L, Wang ZZ. Extrinsic regulation of cardiomyocyte differentiation of embryonic stem cells[J]. J Cell Biochem, 2008,104(1):119-128.
[18] Akasha AA, Sotiriadou I, Doss MX, et al. Entrapment of embryonic stem cells-derived cardiomyocytes in macroporous biodegradable microspheres: preparation and characterization[J]. Cell Physiol Biochem, 2008,22(5-6):665-672.
[19] Ke Q, Yang Y, Rana J, et al. Embryonic stem cells cultured in biodegradable scaffold repair infarcted myocardium in mice[J]. Acta Physiologica Sinica,2005，57(6):673-681.
[20]Benetti F, Penherrera E, Maldonado T, et al. Direct myocardial implantation of human fetal stem cells in heart failure patients: long-term results[J]. The heart surgery forum. 2010,13(1): E31-5.
[21] Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro[J]. Journal of Clinical Investigation,1999,103(5):697-705.
[22] Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ,2014, 21(2):216-25.
[23] Clifford, DM, Fisher, SA, Brunskill, SJ, et al. Stem cell treatment for acute myocardial infarction[J]. Cochrane Database Syst. Rev. 2012; 2, CD006536.
[24] Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes frominduced pluripotent stem cells[J]. Circulation, 2008, 118(5): 507–517.
[25] Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells[J]. Circulation,2008,118(5):498–506.
[26] Zhang J, Klos M, Wilson GF, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method[J]. Circulation research. 2012,111(9):1125-36.
[27] Zwi-Dantsis L, Huber I, Habib M, et al. Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients[J]. Eur Heart J, 2012,34(21):1575-86.
[28] Zhao Q, Cai H, Zhan Y, Li B, Hu S, Sun N. Applications of human-induced pluripotent stem cells in the investigation of inherited cardiomyopathy[J]. International journal of cardiology. 2014,177(2):604-6.
